A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Subcutaneous AC2037 in Obese or Overweight Subjects.
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2014
At a glance
- Drugs Davalintide (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 28 Aug 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Aug 2009 Planned end date changed from 1 Aug 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.
- 22 Nov 2008 New trial record.